Filip Odqvist
About Filip Odqvist
Filip Odqvist is the Business Unit Director for Hematology & Oncology at Bristol Myers Squibb, overseeing operations in Puerto Rico and the Caribbean. He has over a decade of experience in the pharmaceutical industry, including significant roles at Celgene, IMS Consulting, and sanofi-aventis.
Current Role at Bristol Myers Squibb
Filip Odqvist currently serves as the Business Unit Director Hematology & Oncology for Puerto Rico and the Caribbean at Bristol Myers Squibb. In this capacity, he is responsible for overseeing the business unit's operations, strategy, and performance within the specified regions. Filip joined Bristol Myers Squibb in February 2021, bringing with him extensive experience in both hematology and oncology.
Previous Role at Celgene
Before joining Bristol Myers Squibb, Filip Odqvist worked at Celgene as the Director of U.S. Marketing Hematology Launch Lead Fedratinib. He held this position from 2013 to 2021, making significant contributions over eight years. In his role, Filip was instrumental in leading the U.S. marketing launch for Fedratinib, a treatment in the field of hematology.
Consultant Experience at IMS Consulting
From 2009 to 2013, Filip Odqvist was employed as a Consultant at IMS Consulting. During his four-year tenure in the Greater New York City Area, he provided strategic consulting services, utilizing data and insights to inform business decisions in the pharmaceutical industry.
Early Career at Sanofi-Aventis
Filip Odqvist began his career at sanofi-aventis, where he served as a Project Leader focused on Access to Medicines from 2007 to 2008. This role involved leading projects aimed at improving access to essential medicines, reflecting Filip's early commitment to healthcare outcomes.
Educational Background
Filip Odqvist holds a Bachelor of Arts in Economics from Middlebury College, where he studied from 2003 to 2007. His strong foundation in economics has been central to his approach in various roles throughout his career, particularly in the pharmaceutical industry.